JP2007197439A5 - - Google Patents

Download PDF

Info

Publication number
JP2007197439A5
JP2007197439A5 JP2007002808A JP2007002808A JP2007197439A5 JP 2007197439 A5 JP2007197439 A5 JP 2007197439A5 JP 2007002808 A JP2007002808 A JP 2007002808A JP 2007002808 A JP2007002808 A JP 2007002808A JP 2007197439 A5 JP2007197439 A5 JP 2007197439A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
nucleic acid
protein
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007002808A
Other languages
English (en)
Other versions
JP2007197439A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2007197439A publication Critical patent/JP2007197439A/ja
Publication of JP2007197439A5 publication Critical patent/JP2007197439A5/ja
Pending legal-status Critical Current

Links

Claims (24)

  1. 配列番号:2に記載のアミノ酸配列に対して少なくとも90%の同一性を有するアミノ酸配列を有するタンパク質をコードするヌクレオチド配列を含んでなる核酸において、当該タンパク質が、(a)免疫原として使用した場合、全長メソセリン(配列番号:2)を認識する抗体を生成し、或いは中皮腫細胞又はメソセリンを発現する卵巣癌細胞を有する患者からのT細胞により認識される、ことを特徴とする核酸。
  2. 前記ヌクレオチド配列が、配列番号:2にアミノ酸配列を有するタンパク質をコードする、請求項1に記載の核酸。
  3. 配列番号:1に記載のヌクレオチド配列を有する、請求項1又は2に記載の核酸。
  4. プロモーターに作用可能に連結されている、請求項1〜3のいずれか1項に記載の核酸。
  5. 請求項1〜4のいずれか1項に記載の核酸を含んでなる発現ベクター。
  6. 請求項5に記載の発現ベクターを含んでなる宿主細胞。
  7. 請求項1〜4のいずれか1項に記載の核酸を含んでなる組成物。
  8. 配列番号:2に記載のアミノ酸配列に対して少なくとも90%の同一性を有するアミノ酸配列を有するタンパク質において、当該タンパク質が、(a)免疫原として使用した場合、全長メソセリン(配列番号:2)を認識する抗体を生成し、或いは中皮腫細胞又はメソセリンを発現する卵巣癌細胞を有する患者からのT細胞により認識される、ことを特徴とするタンパク質。
  9. 配列番号:2に記載のアミノ酸配列を含んでなる、請求項8に記載のタンパク質。
  10. 請求項8又は9に記載のタンパク質を含んでなる組成物。
  11. アジュバントを更に含んでなる、請求項10に記載の組成物。
  12. 請求項8又は9に記載のタンパク質により哺乳類を免疫することを含んでなる、メソセリンに対する抗体の製造方法。
  13. 配列番号:2に記載のアミノ酸残基239−628のアミノ酸配列に対して少なくとも90%の同一性を有するアミノ酸配列を有するタンパク質をコードするヌクレオチド配列を含んでなる核酸において、当該タンパク質が、(a)免疫原として使用した場合、全長メソセリン(配列番号:2)を認識する抗体を生成し、或いは中皮腫細胞又はメソセリンを発現する卵巣癌細胞を有する患者からのT細胞により認識される、ことを特徴とする核酸。
  14. 前記ヌクレオチド配列が、配列番号:2に記載のアミノ酸残基239−628のアミノ酸配列を有するタンパク質をコードする、請求項13に記載の核酸。
  15. 配列番号:1に記載のヌクレオチド1056−2063のヌクレオチド配列を有する、請求項13又は14に記載の核酸。
  16. プロモーターに作用可能に連結されている、請求項13〜15のいずれか1項に記載の核酸。
  17. 請求項13〜16のいずれか1項に記載の核酸を含んでなる発現ベクター。
  18. 請求項17に記載の発現ベクターを含んでなる宿主細胞。
  19. 請求項13〜16のいずれか1項に記載の核酸を含んでなる組成物。
  20. 配列番号:2に記載のアミノ酸残基239−628のアミノ酸配列に対して少なくとも90%の同一性を有するアミノ酸配列を有するポリペプチドにおいて、当該ポリペプチドが、(a)免疫原として使用した場合、全長メソセリン(配列番号:2)を認識する抗体を生成し、或いは中皮腫細胞又はメソセリンを発現する卵巣癌細胞を有する患者からのT細胞により認識される、ことを特徴とするポリペプチド。
  21. 配列番号:2に記載のアミノ酸残基239−628のアミノ酸配列を含んでなる、請求項20に記載のポリペプチド。
  22. 請求項20又は21に記載のタンパク質を含んでなる組成物。
  23. アジュバントを更に含んでなる、請求項22に記載の組成物。
  24. 請求項20又は21に記載のポリペプチドにより哺乳類を免疫することを含んでなる、メソセリンに対する抗体の製造方法。
JP2007002808A 1996-01-05 2007-01-10 中皮抗原及びそれを標的化するための方法及びキット Pending JP2007197439A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1016696P 1996-01-05 1996-01-05
US60/010,166 1996-01-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP9525355A Division JP2000505787A (ja) 1996-01-05 1997-01-03 中皮抗原及びそれを標的化するための方法及びキット

Publications (2)

Publication Number Publication Date
JP2007197439A JP2007197439A (ja) 2007-08-09
JP2007197439A5 true JP2007197439A5 (ja) 2009-04-16

Family

ID=21744267

Family Applications (2)

Application Number Title Priority Date Filing Date
JP9525355A Withdrawn JP2000505787A (ja) 1996-01-05 1997-01-03 中皮抗原及びそれを標的化するための方法及びキット
JP2007002808A Pending JP2007197439A (ja) 1996-01-05 2007-01-10 中皮抗原及びそれを標的化するための方法及びキット

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP9525355A Withdrawn JP2000505787A (ja) 1996-01-05 1997-01-03 中皮抗原及びそれを標的化するための方法及びキット

Country Status (9)

Country Link
US (2) US6083502A (ja)
EP (1) EP0871492B1 (ja)
JP (2) JP2000505787A (ja)
AT (1) ATE254931T1 (ja)
AU (1) AU703769B2 (ja)
CA (1) CA2241604C (ja)
DE (1) DE69726404T2 (ja)
ES (1) ES2212071T3 (ja)
WO (1) WO1997025068A2 (ja)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314632B1 (en) * 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
CA2295971C (en) * 1997-07-11 2011-02-08 THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Pseudomonas exotoxin a-like chimeric immunogens
US6809184B1 (en) * 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
CA2369433A1 (en) * 1999-02-26 2000-08-31 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US6770445B1 (en) * 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US7745159B2 (en) * 1999-02-26 2010-06-29 Nathalie B Scholler Methods and compositions for diagnosing carcinomas
DK1180123T3 (da) * 1999-05-27 2008-10-13 Us Gov Health & Human Serv Immunkonjugater, der har höj bindingsaffinitet
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US6987024B1 (en) * 2000-04-10 2006-01-17 Raven Biotechnologies, Inc. Human ovarian mesothelial cells and methods of isolation and uses thereof
AU2002338446A1 (en) * 2001-01-23 2002-11-05 University Of Rochester Medical Center Methods of producing or identifying intrabodies in eukaryotic cells
PT2371854E (pt) 2001-03-09 2014-08-25 Jackson H M Found Military Med Indução da imunidade tumoral por variantes da proteína de ligação ao folato
WO2004006837A2 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
KR101192652B1 (ko) * 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
MXPA05008340A (es) * 2003-02-06 2006-03-13 Cerus Corp Microbios de vida libre modificados, composiciones de vacuna y metodos de uso de los mismos.
US20040180387A1 (en) 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
JP2007525971A (ja) * 2003-08-05 2007-09-13 モルフォテック、インク. 癌に関連する変異体細胞表面分子
US7399793B2 (en) * 2003-10-31 2008-07-15 Basf Corporation Coating composition curable with ultraviolet radiation
SG10201701737XA (en) 2003-11-06 2017-04-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
WO2005072341A2 (en) * 2004-01-21 2005-08-11 Fujirebio America, Inc. Detection of mesothelin-/megakaryocyte potentiating factor-related peptides in peritoneal fluid for assessment of the peritoneum and the peritoneal cavity
US20060014221A1 (en) * 2004-01-21 2006-01-19 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of mesothelioma
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
WO2006099141A2 (en) 2005-03-10 2006-09-21 Morphotek, Inc. Anti-mesothelin antibodies
AU2006241099B2 (en) 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
ES2532942T3 (es) 2006-03-01 2015-04-06 Aduro Biotech Listeria obtenida por ingeniería genética y métodos de uso de la misma
US20070207171A1 (en) * 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
US7935804B2 (en) * 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
WO2008105814A2 (en) * 2006-08-22 2008-09-04 Los Alamos National Security, Llc Miniturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids
CA2685308A1 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
SG183023A1 (en) 2007-07-16 2012-08-30 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
RU2557319C2 (ru) 2007-07-16 2015-07-20 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
JP2009028871A (ja) 2007-07-30 2009-02-12 Denso Wave Inc ロボット制御装置
PL2195017T3 (pl) 2007-10-01 2015-03-31 Bristol Myers Squibb Co Ludzkie antyciała, które wiążą mezotelinę i ich zastosowania
US9023351B2 (en) * 2007-11-26 2015-05-05 Bayer Intellectual Property Gmbh Anti-mesothelin antibodies and uses thereof
WO2009099728A1 (en) 2008-01-31 2009-08-13 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
US8357783B2 (en) * 2008-03-27 2013-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human anti-mesothelin monoclonal antibodies
US8785134B2 (en) * 2008-11-10 2014-07-22 The Mitre Corporation Glycoprotein vesicles and their methods of use
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
ES2544805T3 (es) 2009-09-11 2015-09-04 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Exotoxina A de Pseudomonas mejorada con inmunogenicidad reducida
WO2011051350A1 (en) * 2009-10-27 2011-05-05 Ucb Pharma S.A. Function modifying nav 1.7 antibodies
WO2011100455A1 (en) 2010-02-12 2011-08-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibition of antibody responses to foreign proteins
AU2011349443B2 (en) 2010-12-20 2015-12-24 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
KR101878889B1 (ko) 2011-04-20 2018-07-16 메사 바이오테크, 인크. 핵산의 왕복 증폭 반응
CN103648525B (zh) 2011-05-06 2016-08-24 由卫生与公共服务部部长代表的美国政府 靶向间皮素的重组免疫毒素
KR20140054140A (ko) * 2011-07-27 2014-05-08 베일러 리서치 인스티튜트 췌장암에 대한 수지상 세포(dc) - 백신 치료요법
US9127081B2 (en) 2012-05-10 2015-09-08 Washington University Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide and nucleic acids encoding the same
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
EP2888282B1 (en) 2012-08-21 2018-03-14 The U.S.A. as represented by the Secretary, Department of Health and Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
CA2885761C (en) 2012-09-27 2021-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
WO2014182532A1 (en) 2013-05-07 2014-11-13 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Mesothelin-specific immunocytokine and use thereof
AU2015320678B2 (en) 2014-09-23 2021-07-22 Genentech, Inc. Method of using anti-CD79b immunoconjugates
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016196506A1 (en) 2015-05-29 2016-12-08 Galena Biopharma, Inc. PEPTIDE VACCINE THERAPY FOR TREATMENT OF FRα-EXPRESSING TUMORS
CN109069597A (zh) 2015-12-22 2018-12-21 诺华股份有限公司 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗
ES2944597T3 (es) 2015-12-30 2023-06-22 Novartis Ag Terapias con células efectoras inmunitarias de eficacia mejorada
PT3405212T (pt) 2016-01-19 2020-08-25 Pfizer Vacinas para o cancro
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
SG11201809041TA (en) 2016-04-15 2018-11-29 Novartis Ag Compositions and methods for selective protein expression
MA45169A (fr) 2016-05-31 2019-04-10 Sellas Life Sciences Group Inc Thérapie vaccinale pour le traitement du cancer de l'endomètre et de l'ovaire
EP3490590A2 (en) 2016-08-01 2019-06-05 Novartis AG Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
GB201616699D0 (en) 2016-09-30 2016-11-16 Mab Designs Ltd Antibodies
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
CN111683962A (zh) 2017-11-10 2020-09-18 美国政府(由卫生和人类服务部的部长所代表) 靶向肿瘤抗原的嵌合抗原受体
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020146182A1 (en) 2019-01-08 2020-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
BR112021015783A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
BR112021015672A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
TW202321296A (zh) 2021-10-06 2023-06-01 美商鏈接免疫療法公司 抗間皮素抗原結合分子及其用途
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0377657A1 (en) * 1987-08-19 1990-07-18 Centocor, Inc. Human ovarian tumor-associated antigen specific for monoclonal antibody ov-tl3
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
ES2121792T3 (es) * 1990-10-12 1998-12-16 Us Health Anticuerpo monoclonal.
JP3328341B2 (ja) * 1991-12-27 2002-09-24 中外製薬株式会社 新規な巨核球増幅因子
JP3490125B2 (ja) * 1992-10-23 2004-01-26 中外製薬株式会社 巨核球増幅因子をコードする遺伝子
IL107366A (en) * 1992-10-23 2003-03-12 Chugai Pharmaceutical Co Ltd Genes coding for megakaryocyte potentiator

Similar Documents

Publication Publication Date Title
JP2007197439A5 (ja)
JP2005120106A5 (ja)
JP2009261399A5 (ja)
JP2012095652A5 (ja)
EP2821505A3 (en) Nucleotide-specific recognition sequences for designer tal effectors
NZ741567A (en) Antibodies for treatment of cancer expressing claudin 6
JP2018537087A5 (ja)
JP2009268467A5 (ja)
JP2018512856A5 (ja)
JP2017513479A5 (ja)
RU2012122173A (ru) Варианты альбумина
JP2009511000A5 (ja)
JP2014500724A5 (ja)
JP2010227116A5 (ja)
WO2007031875A3 (en) Modified antigen binding molecules with altered cell signaling activity
JP2015096070A5 (ja)
TW200738880A (en) Nucleic acids encoding TGEV and PRRSV sequences for improved expression of PRRSV sequences
JP2009201525A5 (ja)
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
JP2011062217A5 (ja)
GB201003701D0 (en) System for the expression of a protein
JP2018531624A5 (ja)
UA108081C2 (uk) Модифікація рекомбінантного аденовірусу імуногенними епітопами білка circumsporozoite плазмодія
JP2008545393A5 (ja)
WO2012018907A3 (en) Polypeptides for treating and/or limiting influenza infection